Read more here: Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
Read more here: Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
Continue reading here: Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane...
Read more: OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
Here is the original post: Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
Read more: Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
Read this article: BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
More here: Inozyme Pharma to Present at the Jefferies Healthcare Conference
See original here: Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
Originally posted here: Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
See the rest here: Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual...
Recent Comments